UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 427

Sortiert nach

The importance of resistance to direct antiviral drugs in HCV infection in clinical practice

Journal of hepatology, 2016-02, Vol.64 (2), p.486-504

Sarrazin, Christoph

2016

Volltextzugriff (PDF)

Antiviral therapy of hepatitis C in 2014: Do we need resistance testing?

Antiviral research, 2014-05, Vol.105, p.64-71

2014

Volltextzugriff (PDF)

Treatment predictors of a sustained virologic response in hepatitis B and C

Journal of hepatology, 2008-10, Vol.49 (4), p.634-651

2008

Volltextzugriff (PDF)

Treatment failure with DAA therapy: Importance of resistance

Journal of hepatology, 2021-06, Vol.74 (6), p.1472-1482

Sarrazin, Christoph

2021

Volltextzugriff (PDF)

Performance of Transient Elastography for the Staging of Liver Fibrosis: A Meta-Analysis

Gastroenterology (New York, N.Y. 1943), 2008-04, Vol.134 (4), p.960-974.e8

2008

Volltextzugriff (PDF)

The role of resistance in HCV treatment

Baillière's best practice & research. Clinical gastroenterology, 2012-08, Vol.26 (4), p.487-503

2012

Volltextzugriff (PDF)

Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients

PloS one, 2015-08, Vol.10 (8), p.e0134395

2015

Volltextzugriff (PDF)

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus–infected patients

Hepatology (Baltimore, Md.), 2009-12, Vol.50 (6), p.1709-1718

2009

Volltextzugriff (PDF)

Viral Determinants of Resistance to Treatment in Patients with Hepatitis C

Clinical Microbiology Reviews, 2007-01, Vol.20 (1), p.23-38

2007

Volltextzugriff (PDF)

Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients

Journal of hepatology, 2011-03, Vol.54 (3), p.415-421

2011

Volltextzugriff (PDF)

Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens

Journal of hepatology, 2016-09, Vol.65 (3), p.473-482

2016

Volltextzugriff (PDF)

Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region

Antiviral research, 2015-04, Vol.116, p.10-16

2015

Volltextzugriff (PDF)

Divergent preS Sequences in Virion-Associated Hepatitis B Virus Genomes and Subviral HBV Surface Antigen Particles From HBV e Antigen-Negative Patients

The Journal of infectious diseases, 2018-06, Vol.218 (1), p.114-123

2018

Volltextzugriff (PDF)

Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection

Gastroenterology (New York, N.Y. 1943), 2010-02, Vol.138 (2), p.447-462

2010

Volltextzugriff (PDF)

Telaprevir and pegylated interferon–alpha‐2a inhibit wild‐type and resistant genotype 1 hepatitis C virus replication in patients

Hepatology (Baltimore, Md.), 2007-09, Vol.46 (3), p.631-639

2007

Volltextzugriff (PDF)

Biliary strictures and recurrence after liver transplantation for primary sclerosing cholangitis: A retrospective multicenter analysis

Liver transplantation, 2016-01, Vol.22 (1), p.42-52

2016

Volltextzugriff (PDF)

Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants

Hepatology (Baltimore, Md.), 2019-09, Vol.70 (3), p.771-787

2019

Volltextzugriff (PDF)

Stand der nationalen und globalen Hepatitis-C-Elimination

Innere Medizin (Heidelberg, Germany), 2024-04, Vol.65 (4), p.308-317

2024

Volltextzugriff (PDF)

Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 Versus 72 Weeks of Peginterferon-Alfa-2a Plus Ribavirin

Gastroenterology (New York, N.Y. 1943), 2006-04, Vol.130 (4), p.1086-1097

2006

Volltextzugriff (PDF)

Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study

Journal of hepatology, 2012-03, Vol.56 (3), p.520-526

2012

Volltextzugriff (PDF)

Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation

PloS one, 2018-06, Vol.13 (6), p.e0197544-e0197544

2018

Volltextzugriff (PDF)

Second-Generation Cobas AmpliPrep/Cobas TaqMan HCV Quantitative Test for Viral Load Monitoring: a Novel Dual-Probe Assay Design

Journal of Clinical Microbiology, 2013-02, Vol.51 (2), p.571-577

2013

Volltextzugriff (PDF)

Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis

BMC gastroenterology, 2010-09, Vol.10 (1), p.103-103, Article 103

2010

Volltextzugriff (PDF)

Hepatitis C “true” late relapse beyond 48 weeks of sustained virologic response after direct acting antiviral therapy

Journal of hepatology, 2017-04, Vol.66 (4), p.862-863

2017

Volltextzugriff (PDF)

Benefit of a clipping device in use in intestinal bleeding and intestinal leakage

Gastrointestinal endoscopy, 2011-08, Vol.74 (2), p.389-397

2011

Volltextzugriff (PDF)

1 – 25 von 427

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(402)
Mit Volltextzugriff
(391)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(275)
Life Sciences & Biomedicine
(249)
Humans
(245)
Gastroenterology & Hepatology
(153)
Female
(140)
Male
(140)
Adult
(127)
Middle Aged
(127)
Antiviral Agents - Therapeutic Use
(105)
Hepatitis C Virus
(102)
Hepacivirus - Genetics
(100)
Hepatitis C, Chronic - Drug Therapy
(100)
Hepatitis C
(85)
Aged
(83)
Infectious Diseases
(79)
Biological And Medical Sciences
(77)
Genotype
(75)
Medical Sciences
(73)
Gastroenterology And Hepatology
(69)
Hepatitis C, Chronic - Virology
(67)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

The importance of resistance to direct antiviral drugs in HCV infection in clinical practice

Antiviral therapy of hepatitis C in 2014: Do we need resistance testing?

Treatment predictors of a sustained virologic response in hepatitis B and C

Treatment failure with DAA therapy: Importance of resistance

Performance of Transient Elastography for the Staging of Liver Fibrosis: A Meta-Analysis

The role of resistance in HCV treatment

Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus–infected patients

Viral Determinants of Resistance to Treatment in Patients with Hepatitis C

Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients

Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens

Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region

Divergent preS Sequences in Virion-Associated Hepatitis B Virus Genomes and Subviral HBV Surface Antigen Particles From HBV e Antigen-Negative Patients

Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection

Telaprevir and pegylated interferon–alpha‐2a inhibit wild‐type and resistant genotype 1 hepatitis C virus replication in patients

Biliary strictures and recurrence after liver transplantation for primary sclerosing cholangitis: A retrospective multicenter analysis

Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants

Stand der nationalen und globalen Hepatitis-C-Elimination

Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 Versus 72 Weeks of Peginterferon-Alfa-2a Plus Ribavirin

Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study

Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation

Second-Generation Cobas AmpliPrep/Cobas TaqMan HCV Quantitative Test for Viral Load Monitoring: a Novel Dual-Probe Assay Design

Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis

Hepatitis C “true” late relapse beyond 48 weeks of sustained virologic response after direct acting antiviral therapy

Benefit of a clipping device in use in intestinal bleeding and intestinal leakage

Suchergebnisse filtern